Combination treatment for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a combination of two medications, entinostat and an oral form of paclitaxel, for people with advanced breast cancer that is hormone receptor positive and HER2-negative. If you've already tried several treatments, this might be a new option to help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced breast cancer that is hormone receptor positive and HER2-negative.
- You have at least one tumor that can be measured on a scan.
- You have already had 2 to 4 lines of treatment, including hormone therapy with a CDK4/6 inhibitor and a chemotherapy called paclitaxel (or similar).
- You are generally active and able to take care of yourself (ECOG score 0-2).
- You are expected to live more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
This trial tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the disease.
This Phase 4 trial compares two chemotherapy combinations to treat stage II–III triple-negative breast cancer. It looks for which regimen works better and is tolerated in people with measurable tumors and good overall health.
This trial tests a new pill (entinostat) combined with a standard hormone therapy (fulvestrant) for people with hormone-receptor-positive, HER2-negative breast cancer that has spread or come back and no longer responds to current hormone treatments. The goal is to see if this combination helps control the cancer longer.
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.